Kerstin Rhiem

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Sibylle Loibl, Karsten E. Weber, Kirsten M. Timms et al. · Annals of Oncology · 2018 · 300 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Sibylle Loibl, Jens Huober, Michael Braun et al. · Annals of Oncology · 2022 · 244 citations

Medicine, Oncology, Breast Oncology +9

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · Journal of Clinical Oncology · 2019 · 156 citations

Medicine, Oncology, Pharmacology +17